Charles Schwab’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $44.4M | Buy |
591,423
+19,323
| +3% | +$1.24M | 0.01% | 1332 |
|
|
2026
Q1 | $32.2M | Buy |
572,100
+23,179
| +4% | +$1.51M | ﹤0.01% | 1463 |
|
|
2025
Q4 | $44M | Sell |
548,921
-12,891
| -2% | -$866K | 0.01% | 1241 |
|
|
2025
Q3 | $27.4M | Sell |
561,812
-316
| -0.1% | -$19.6K | ﹤0.01% | 1540 |
|
|
2025
Q2 | $41.9M | Buy |
562,128
+6,101
| +1% | +$404K | 0.01% | 1204 |
|
|
2025
Q1 | $35.3M | Buy |
556,027
+4,834
| +0.9% | +$329K | 0.01% | 1295 |
|
|
2024
Q4 | $43M | Buy |
551,193
+8,477
| +2% | +$681K | 0.01% | 1241 |
|
|
2024
Q3 | $43.6M | Sell |
542,716
-4,067
| -0.7% | -$329K | 0.01% | 1211 |
|
|
2024
Q2 | $45.2M | Sell |
546,783
-2
| -0% | -$176 | 0.01% | 1152 |
|
|
2024
Q1 | $46.7M | Buy |
546,785
+12,091
| +2% | +$949K | 0.01% | 1089 |
|
|
2023
Q4 | $45.7M | Buy |
534,694
+8,901
| +2% | +$770K | 0.01% | 1038 |
|
|
2023
Q3 | $47.1M | Buy |
525,793
+33,294
| +7% | +$2.97M | 0.01% | 910 |
|
|
2023
Q2 | $41.9M | Buy |
492,499
+6,202
| +1% | +$524K | 0.01% | 975 |
|
|
2023
Q1 | $40.2M | Sell |
486,297
-9,063
| -2% | -$734K | 0.01% | 980 |
|
|
2022
Q4 | $39M | Sell |
495,360
-10,875
| -2% | -$874K | 0.01% | 972 |
|
|
2022
Q3 | $37.5M | Buy |
506,235
+5,123
| +1% | +$368K | 0.01% | 945 |
|
|
2022
Q2 | $32.7M | Buy |
501,112
+1,349
| +0.3% | +$79.8K | 0.01% | 1039 |
|
|
2022
Q1 | $31.6M | Buy |
499,763
+35,078
| +8% | +$1.91M | 0.01% | 1187 |
|
|
2021
Q4 | $24.6M | Buy |
464,685
+32,469
| +8% | +$1.98M | 0.01% | 1411 |
|
|
2021
Q3 | $30.5M | Buy |
432,216
+10,861
| +3% | +$685K | 0.01% | 1211 |
|
|
2021
Q2 | $28.1M | Buy |
421,355
+128,346
| +44% | +$9.08M | 0.01% | 1299 |
|
|
2021
Q1 | $32.5M | Buy |
293,009
+1,258
| +0.4% | +$156K | 0.01% | 1130 |
|
|
2020
Q4 | $34.6M | Sell |
291,751
-8,101
| -3% | -$872K | 0.01% | 1014 |
|
|
2020
Q3 | $26.2M | Sell |
299,852
-22,364
| -7% | -$1.95M | 0.01% | 1032 |
|
|
2020
Q2 | $28.9M | Sell |
322,216
-99,693
| -24% | -$10.1M | 0.01% | 926 |
|
|
2020
Q1 | $42M | Buy |
421,909
+25,912
| +7% | +$2.81M | 0.02% | 594 |
|
|
2019
Q4 | $45.5M | Buy |
395,997
+11,767
| +3% | +$1.42M | 0.02% | 682 |
|
|
2019
Q3 | $48.5M | Sell |
384,230
-79,137
| -17% | -$10M | 0.03% | 600 |
|
|
2019
Q2 | $55.8M | Sell |
463,367
-23,201
| -5% | -$2.28M | 0.03% | 516 |
|
|
2019
Q1 | $42.6M | Buy |
486,568
+14,753
| +3% | +$1.34M | 0.03% | 623 |
|
|
2018
Q4 | $47.2M | Sell |
471,815
-62,390
| -12% | -$6.55M | 0.04% | 476 |
|
|
2018
Q3 | $61.2M | Buy |
534,205
+1,606
| +0.3% | +$166K | 0.04% | 432 |
|
|
2018
Q2 | $47.8M | Buy |
532,599
+60,135
| +13% | +$5.08M | 0.03% | 522 |
|
|
2018
Q1 | $34.6M | Sell |
472,464
-82,188
| -15% | -$5.64M | 0.03% | 659 |
|
|
2017
Q4 | $32.2M | Sell |
554,652
-34,727
| -6% | -$1.83M | 0.03% | 652 |
|
|
2017
Q3 | $26.4M | Buy |
589,379
+20,925
| +4% | +$869K | 0.02% | 712 |
|
|
2017
Q2 | $22.4M | Buy |
568,454
+24,451
| +4% | +$1M | 0.02% | 777 |
|
|
2017
Q1 | $22.1M | Buy |
544,003
+93,948
| +21% | +$3.67M | 0.02% | 770 |
|
|
2016
Q4 | $18.1M | Buy |
450,055
+54,130
| +14% | +$2.04M | 0.02% | 815 |
|
|
2016
Q3 | $14.3M | Sell |
395,925
-71,378
| -15% | -$2.45M | 0.02% | 910 |
|
|
2016
Q2 | $13.5M | Buy |
467,303
+208,101
| +80% | +$6.29M | 0.02% | 870 |
|
|
2016
Q1 | $9.07M | Buy |
259,202
+43,402
| +20% | +$1.4M | 0.01% | 1103 |
|
|
2015
Q4 | $6.96M | Buy |
215,800
+5,202
| +2% | +$169K | 0.01% | 1294 |
|
|
2015
Q3 | $6.81M | Buy |
210,598
+13,227
| +7% | +$498K | 0.01% | 1252 |
|
|
2015
Q2 | $8.16M | Buy |
197,371
+13,377
| +7% | +$564K | 0.01% | 1192 |
|
|
2015
Q1 | $8.27M | Buy |
183,994
+11,182
| +6% | +$467K | 0.01% | 1139 |
|
|
2014
Q4 | $6.47M | Buy |
172,812
+6,052
| +4% | +$222K | 0.01% | 1241 |
|
|
2014
Q3 | $5.82M | Buy |
166,760
+661
| +0.4% | +$23.6K | 0.01% | 1242 |
|
|
2014
Q2 | $5.86M | Buy |
166,099
+4,110
| +3% | +$137K | 0.01% | 1267 |
|
|
2014
Q1 | $5.28M | Sell |
161,989
-3,468
| -2% | -$133K | 0.01% | 1296 |
|
|
2013
Q4 | $6.97M | Buy |
165,457
+5,032
| +3% | +$207K | 0.01% | 996 |
|
|
2013
Q3 | $6.41M | Buy |
160,425
+7,848
| +5% | +$329K | 0.01% | 965 |
|
|
2013
Q2 | $6.47M | Buy |
+152,577
| New | +$6.18M | 0.01% | 831 |
|
Other funds holding HAE
AI
Charles Schwab's HAE Position: Q2 2026 in Review
Charles Schwab increased its Haemonetics (HAE) stake by 3.4% in Q2 2026, buying an estimated $1.24M and bringing the position to 591,423 shares worth $44.4M. The position accounts for 0.01% of the portfolio, ranked #1332.
Charles Schwab first reported a position in HAE in Q2 2013 and has held it in 53 quarters since. The position peaked at $61.2M in Q3 2018. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.
- Charles Schwab held 591,423 shares of Haemonetics worth $44.4M as of Q2 2026.
- Charles Schwab bought 19,323 Haemonetics shares in Q2 2026, an estimated $1.24M.
- Haemonetics made up 0.01% of Charles Schwab's portfolio in Q2 2026, its #1332 holding.
- Charles Schwab first reported a position in Haemonetics in Q2 2013 and has held it in 53 quarters since.
- Charles Schwab's Haemonetics position peaked at $61.2M in Q3 2018.
- 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.